New 52 Week Low Today

NuCana PLC NCNA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/18/24 EDT
3.79UNCH (UNCH)
Volume
86,144
52 week range
3.61 - 23.75
Loading...
  • Open4.08
  • Day High4.20
  • Day Low3.61
  • Prev Close3.97
  • 52 Week High23.75
  • 52 Week High Date04/19/23
  • 52 Week Low3.61
  • 52 Week Low Date04/18/24

Key Stats

  • Market Cap320,558.19
  • Shares Out84,580.00
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-48.75

KEY STATS

  • Open4.08
  • Day High4.20
  • Day Low3.61
  • Prev Close3.97
  • 52 Week High23.75
  • 52 Week High Date04/19/23
  • 52 Week Low3.61
  • 52 Week Low Date04/18/24
  • Market Cap320,558.19
  • Shares Out84,580.00
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-48.75

RATIOS/PROFITABILITY

  • EPS (TTM)-20.46
  • P/E (TTM)-0.19
  • Fwd P/E (NTM)-0.00
  • EBITDA (TTM)-38.023M
  • ROE (TTM)-103.51%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)2.66%

EVENTS

  • Earnings Date05/15/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On NuCana PLC

 

Profile

MORE
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid...
Andrew Kay
Non-Executive Independent Chairman of the Board
Hugh Griffith
Chief Executive Officer, Co-Founder, Executive Director
Donald Munoz
Chief Financial Officer
Address
Lochside House, 3 Lochside Way
Edinburgh
EH12 9DT
United Kingdom

Top Peers

SYMBOLLASTCHG%CHG
ONVO
Organovo Holdings Inc
1.15UNCHUNCH
MNPR
Monopar Therapeutics Inc
0.678UNCHUNCH
ATHE
Alterity Therapeutics Ltd
2.14UNCHUNCH
VIRI
Virios Therapeutics Inc
0.4499UNCHUNCH
GNPX
Genprex Inc
2.21UNCHUNCH